Seres Therapeutics (MCRB) Q3 2026 earnings review
Seres Therapeutics halves its operating costs, but cash runs low
Seres Therapeutics, a developer of oral bacterial drugs, halved its underlying spending while waiting for a partner to fund its clinical trials. Excluding a non-cash charge for exiting a building lease, operating expenses fell 52% from a year ago to $11 million by our math. Interim chief executive Richard Kender outlined plans to test lead drug SER-155 for preventing gut inflammation in cancer immunotherapy patients, but every trial remains on hold until new funding arrives.
| Operating expenses, excluding lease charges | $11.0M -52% from a year ago by our math |
|---|---|
| Cash plus October Nestlé payment | $30.0M by our math ($17.5M at Q3 end) |
| Operating lease liabilities | $35.8M -57% from the end of 2025 |
| Cash outlook | Unchanged funds operations through Q1 2027 |
⚖️ Verdict: 🔴 Bearish
The story got worse because the clock ticked down to two quarters of remaining cash without a partnership deal, and detailed trial slides showed weaker durability in the new colitis program. While 12 of 15 colitis patients improved without steroids at Day 15, seven of those 12 needed gut-targeted immunosuppressives by Day 43, and the new prevention plan will not even reach regulators until the first quarter of 2027.
The question now is whether Seres can sign a licensing partner before its cash runs out at the end of March 2027. Either the new Nature Medicine publication and colitis plan attract a pharmaceutical partner to fund the trials, or the company must seek emergency financing on harsh terms. A partnership announcement before the end of the first quarter of 2027 will decide it.
🐂 Bull Case
Spending Cuts and Lease Exits Halved Cash Burn
Seres Therapeutics develops oral bacterial drugs to prevent infections and gut inflammation in cancer patients. While seeking a partner to fund its clinical trials, the biotechnology group has cut its operating costs and exited excess lab and office space in Cambridge, Massachusetts.
In July, the company agreed to end its lease at 200 Sidney Street, which "materially eliminates the Company’s obligations under the lease as of December 31, 2026". That agreement triggered a $5.7 million non-cash accounting charge this quarter, following a $5.8 million charge for shrinking another lease in the second quarter.
- Operating expenses excluding lease charges: $11.0 million, down 51.6% from a year ago by our math
- Research and development: $5.6 million, down 55.7% from a year ago
- General and administrative costs: $5.4 million, down 42.5% from a year ago
These reductions matter because Seres has collected its final milestone payment from selling VOWST, its first approved gut drug, to Nestlé Health Science. Lower overhead and smaller rent bills starting in 2027 will stretch its remaining cash while management negotiates with potential partners.
What to watch: first-quarter 2027 operating expenses, once the 200 Sidney Street lease ends on December 31. Another drop in quarterly spending would give management more time to sign a partnership deal.
Nature Medicine Publishes Stem-Cell Transplant Data
SER-155 is the company's main experimental drug, a capsule of cultivated bacteria designed to protect the gut lining and stop dangerous bacteria from entering the bloodstream. Its most advanced use is in adults receiving stem-cell transplants from donors (allo-HCT) to treat blood cancer.
On November 3, the medical journal Nature Medicine published the full results from the drug's Phase 1b trial in 34 transplant patients. Patients taking SER-155 had a 77% lower relative risk of bacterial bloodstream infections than those on placebo, and they spent an average of 11.9 fewer days on systemic antibiotics.
Peer-reviewed publication validates the science for potential pharmaceutical partners, because infections are a leading cause of death in the first 100 days after a transplant. The US Food and Drug Administration (FDA) has already agreed to the Phase 2 trial design, which includes an early data check after half the patients finish.
What to watch: any partnership or licensing announcement for SER-155 before the end of the first quarter of 2027. Securing external funding would allow the company to start the Phase 2 transplant study immediately.
🐻 Bear Case
Lead Trials Remain Frozen With Two Quarters of Cash Left
Despite holding FDA agreement on its Phase 2 stem-cell transplant study since early 2026, Seres still cannot afford to start the trial on its own. Interim chief executive Richard Kender said: "We continue to seek capital through partnerships and other sources to advance our programs in irEC and in allo-HCT, which is Phase 2 ready, pending funding."
The drugmaker ended September with $17.5 million in cash and collected its final $12.5 million VOWST buyout payment from Nestlé in October. That $30.0 million total by our math covers operations only through the first quarter of 2027, leaving five months from the November release date to find new money.
Every clinical program in the pipeline now carries a "dependent on funding" condition, including the newly announced colitis prevention study and the SER-428 liquid formulation. Because the company has no remaining payments due from Nestlé, it has no internal cash source left to extend its timeline.
What to watch: financing or partnership disclosures before March 31, 2027. Entering 2027 without a partner would force the company to raise money on unfavorable terms or halt clinical operations.
Over Half of Colitis Responders Needed Local Steroids by Day 43
Seres is expanding SER-155 into immune checkpoint inhibitor-related enterocolitis (irEC), severe gut inflammation and diarrhea caused by cancer immunotherapies such as Keytruda. In July, the company reported that 12 of 15 patients (80%) in an investigator-run treatment study at Memorial Sloan Kettering achieved a clinical response at Day 15 without immunosuppressive drugs.
Detailed slide data this quarter show a less durable picture by Day 43. Only 5 of the 15 patients (33.3% by our math) stayed completely off immunosuppressive drugs through Day 43, while 7 of the 12 initial responders (58.3% by our math) "received non-systemically acting, gastrointestinal-targeted immunosuppressives for mild residual or moderate recurrent symptoms".
This cuts against the headline claim of an immunosuppressive-free treatment, because over half the responders still needed gut-targeted steroids within six weeks. That recurring inflammation helps explain why management now wants to give SER-155 earlier to prevent colitis rather than treat active cases.
What to watch: the FDA's feedback on the proposed colitis prevention study after the first-quarter 2027 submission. If regulators require a large trial to prove prevention, the cost will exceed what Seres can fund alone.
Shifting Colitis Drug to Prevention Adds Regulatory Steps
Following the 15-patient treatment trial at Memorial Sloan Kettering, Seres decided to develop SER-155 to prevent colitis in cancer patients starting immunotherapy, rather than treating it after symptoms begin. Kender said: "We also think this development approach offers a time and capital efficient path to clinical data."
However, the company will not submit the study design to the FDA until the first quarter of 2027—the same quarter its cash runs out. Furthermore, the release notes that optimizing the preventive dose "could include a healthy volunteer study component or a dosing lead-in element" before testing the broader cancer population.
Testing prevention takes more patients than testing treatment, because moderate-to-severe colitis only strikes about 25% of immunotherapy patients, so 75% would not get severe symptoms anyway. Adding a dose-finding lead-in further delays clinical results.
What to watch: the final trial design and patient enrollment target after FDA discussions in early 2027. A mandatory lead-in study would push meaningful efficacy data well into 2028.
💲 Other KPIs
Total current and long-term lease obligations fell 36.9% from last quarter and 56.9% from $83.0 million at the end of 2025, by our math. Exiting the 200 Sidney Street building and shrinking the 101 Cambridgepark Drive lease removed $47.2 million in future rent liabilities, reducing fixed cash drain starting in 2027.
Weighted average diluted shares rose 13.8% from 8.77 million a year ago and 2.4% from the second quarter. The increase stems from at-the-market stock sales completed in late 2025 and ongoing employee stock compensation, diluting existing shareholders while the biotech group searches for non-dilutive partnership capital.
Grant revenue rose 68.9% from $351 thousand a year ago, when the award began, but dipped 19.4% from $736 thousand in the second quarter. The money comes from CARB-X, a non-profit accelerator funding SER-428, a liquid bacterial drug for intensive-care patients on feeding tubes.
🔮 Guidance
Unchanged. Seres still expects its $17.5 million in September cash plus the $12.5 million received from Nestlé in October to fund operations through March 2027. Deep cuts to research, overhead, and facility leases kept the timeline intact without adding extra quarters. The forecast excludes any money from future partnerships or stock sales.
❓ Key Questions
Why has no partner signed onto SER-155 yet?
SER-155 holds FDA Breakthrough Therapy status, an agreed Phase 2 stem-cell transplant protocol since January 2026, and a Nature Medicine publication, yet remains unpartnered with two quarters of cash left.
How much will the 200 Sidney Street exit save annually?
Terminating the lease removed $20.9 million in balance-sheet lease liabilities this quarter, but management has not disclosed the exact dollar reduction in annual cash rent starting in 2027.
How large must a colitis prevention trial be?
Because moderate-to-severe colitis affects only about 25% of immunotherapy patients, proving prevention requires a much larger sample size than the 15-patient treatment trial at Memorial Sloan Kettering.
Why did seven colitis responders need local steroids?
Slide 16 reveals that 7 of the 12 Day-15 responders received gut-targeted immunosuppressives by Day 43 for residual or recurrent symptoms, raising questions about how long a 12-day SER-155 course lasts.